Portage Biotech Highlights Promising Data Presented on STING-Activating Therapy, PORT-5 (STI-001) at AACR 2022 Annual Meeting
Preclinical data shows that PORT-5 (STI-001), a stimulator of interferon genes (
“The promising results showcased in this presentation suggest that we are on the verge of developing a novel approach that could elevate the potential of
The
“This presentation is a recognition of the last two years of intense work on the preclinical package of our drug candidate STI-001 in collaboration with Nicolas Manel’s laboratory at Institut Curie /
Presentation Details:
- Abstract title: Cellular selectivity of
STING stimulation determines priming of anti-tumor T cell responses - Abstract Number: 7829
- Presenter:
Bakhos Jneid , Institut Curie - Session Title:
Late-Breaking Research : Experimental and Molecular Therapeutics 2 - Date/Time:
April 13, 2022 ,9:00 a.m. - 12:30 p.m. CT - Location: Poster Section 16
Data Highlights:
- Delivery of a well-characterized
STING activator, cGAMP, by intra-tumoral injections of virus-like particles (cGAMP-VLP) leads to:- Differentiation of tumor-specific T cells
- Decrease in tumor regulatory T cells (Tregs) that would otherwise suppress an immune response
- Preferential targeting of dendritic cells leading to activation of tumor-specific T cells
- Delivery of PORT-5 (STI-001) showed synergy when combined with an antibody that depletes Tregs, leading to complete and lasting tumor eradication
- Additional synergy demonstrated when PORT-5 (STI-001) was combined with anti-PD1 treatments
- Specific cell targeting of
STING stimulation shapes the anti-tumor T cell response and reveals a therapeutic strategy with T cell modulators, which may address the current limitations ofSTING -based approaches in patients
To learn more, view the announcement from Stimunity at www.stimunity.com.
About
Portage is a clinical-stage immuno-oncology company advancing first-in-class therapies that target known checkpoint resistance pathways to improve long-term treatment response and quality of life in patients with evasive cancers. The Company’s access to next-generation technologies coupled with a deep understanding of biological mechanisms enables the identification of the most promising clinical therapies and product development strategies that accelerate these medicines through the translational pipeline. Portage’s portfolio consists of five diverse platforms, leveraging delivery by intratumorals, nanoparticles, liposomes, aptamers, and virus-like particles. Within these five platforms, Portage has 10 products currently in development with multiple clinical readouts expected through the end of 2023. For more information, please visit www.portagebiotech.com, follow us on Twitter at @PortageBiotech or find us on LinkedIn at
About Stimunity
Stimunity is an early-stage biotech company focused on the development of
Forward-Looking Statements
This news release contains statements about the Company’s information that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, undue reliance should not be placed on them as actual results may differ materially from the forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof, and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, except as required by law.
FOR MORE INFORMATION, PLEASE CONTACT:
Investor Relations
chuck@lifesciadvisors.com
Media Relations
gschanker@lifescicomms.com
Source: Portage Biotech Inc.